Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

During COVID-19 vaccination campaign, possible ChAdOx1-S-associated risks of thrombosis with thrombocytopenia syndrome led to implement ChAdOx1-S/BNT162b2 heterologous vaccination, despite the limited information on its reactogenicity and safety. We conducted a prospective observational post-marketi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Francesca Fortunato, Rosa Prato, Giuseppina Iannelli, Leonardo Ascatigno, Daniela Loconsole, Pier Luigi Lopalco, Domenico Martinelli
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2023-01-01
Saila:	Human Vaccines & Immunotherapeutics
Gaiak:	covid-19 vaccination heterologous primary schedule chadox1-s vaccine bnt162b2 vaccine safety post-marketing surveillance italy
Sarrera elektronikoa:	http://dx.doi.org/10.1080/21645515.2023.2209919
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!